In CKD patients, an increase in myostatin production can be initiated by complications associated with CKD, such as metabolic acidosis, defective insulin signaling, inflammation, oxidative stress, increased angiotensin II levels, abnormal appetite regulation, and impaired microRNA responses [8,33]. Here, MSTN is linked to chronic kidney disease.